Docoh
Loading...

DVA DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Company profile

Ticker
DVA
Exchange
Website
CEO
Javier Rodriguez
Employees
Incorporated
Location
Fiscal year end
Former names
DAVITA HEALTHCARE PARTNERS INC., DAVITA INC, TOTAL RENAL CARE HOLDINGS INC
SEC CIK
IRS number
510354549

DVA stock data

(
)

Calendar

12 Feb 21
17 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from DaVita earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 501.79M 501.79M 501.79M 501.79M 501.79M 501.79M
Cash burn (monthly) 105.18M 58.91M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 375.07M 210.07M n/a n/a n/a n/a
Cash remaining 126.72M 291.72M n/a n/a n/a n/a
Runway (months of cash) 1.2 5.0 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Mar 21 Arway Pamela M Common Stock Sell Dispose S No Yes 109.51 436 47.75K 19,239
15 Mar 21 Berg Charles Common Stock Grant Aquire A No No 0 436 0 12,448
15 Mar 21 Price Paula A Common Stock Grant Aquire A No No 0 436 0 791
15 Mar 21 Desoer Barbara J Common Stock Grant Aquire A No No 0 436 0 436
15 Mar 21 Winstel John D Common Stock Grant Aquire A No No 0 4,590 0 11,111

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

89.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 509 469 +8.5%
Opened positions 89 48 +85.4%
Closed positions 49 66 -25.8%
Increased positions 128 140 -8.6%
Reduced positions 221 208 +6.3%
13F shares
Current Prev Q Change
Total value 13.18B 8.72B +51.2%
Total shares 97.92M 101.81M -3.8%
Total puts 431K 1.16M -62.9%
Total calls 2.14M 1.47M +45.0%
Total put/call ratio 0.2 0.8 -74.4%
Largest owners
Shares Value Change
BRK.A Berkshire Hathaway 36.1M $4.24B 0.0%
Vanguard 8.61M $1.01B -6.0%
BLK Blackrock 5.94M $697.32M -6.8%
STT State Street 3.6M $422.39M -9.1%
Dimensional Fund Advisors 2.46M $288.5M -4.1%
LSV Asset Management 2.39M $280.57M -1.8%
BK Bank Of New York Mellon 1.96M $230.27M -17.3%
Norges Bank 1.65M $193.62M NEW
IVZ Invesco 1.57M $184.62M +37.6%
Robeco Institutional Asset Management B.V. 1.52M $178.18M -12.2%
Largest transactions
Shares Bought/sold Change
Norges Bank 1.65M +1.65M NEW
AMP Ameriprise Financial 479.03K -1M -67.6%
Vanguard 8.61M -547.61K -6.0%
Schroder Investment Management 551.04K -514.95K -48.3%
BLK Blackrock 5.94M -430.17K -6.8%
IVZ Invesco 1.57M +429.76K +37.6%
BK Bank Of New York Mellon 1.96M -411.37K -17.3%
JPM JPMorgan Chase & Co. 297.18K -406.32K -57.8%
STT State Street 3.6M -360.46K -9.1%
Ajo 21.98K -283.88K -92.8%

Financial report summary

?
Competition
FMCFibroGenAmerican Renal Associates
Risks
  • Risks Related to the Operation of our Business
  • We face various risks related to the dynamic and evolving novel coronavirus pandemic, any of which may have a material adverse impact on us.
  • Our business is subject to a complex set of governmental laws, regulations and other requirements and any failure to adhere to those requirements, or any changes in those requirements, could have a material adverse effect on our business, results of operations, financial condition and cash flows, could materially harm our stock price, and in some circumstances, could materially harm our reputation.
  • Changes in federal and state healthcare legislation or regulations could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches or suffer losses to our data and information technology assets, any of which could have a material adverse effect on our business, results of operations, financial condition and cash flows or materially harm our reputation.
  • We continuously have ongoing negotiations with commercial payors, and if the average rates that commercial payors pay us decline significantly, if patients in commercial plans are subject to restriction in plan designs or if we are unable to maintain contracts with payors with competitive terms, including, without limitation, reimbursement rates, scope and duration of coverage and in-network benefits, it would have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If the number or percentage of patients with higher-paying commercial insurance declines, it could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If we are not able to successfully implement our strategy with respect to home-based dialysis, including maintaining our existing business and further developing our capabilities in a complex and highly regulated environment, it could have a material adverse effect on our business, results of operations, financial condition and cash flows, and could materially harm our reputation.
  • Changes in the structure of and payment rates under the Medicare ESRD program could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Changes in clinical practices, payment rates or regulations impacting pharmaceuticals could have a material adverse effect on our business, results of operations, financial condition, and cash flows and negatively impact our ability to care for patients.
  • Changes in state Medicaid or other non-Medicare government-based programs or payment rates could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If we are unable to compete successfully, including, without limitation, implementing our growth strategy and/or retaining patients and physicians willing to serve as medical directors, it could materially adversely affect our business, results of operations, financial condition and cash flows.
  • We may engage in acquisitions, mergers, joint ventures or dispositions, which may materially affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and, under certain circumstances, could have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
  • If certain of our suppliers do not meet our needs, if there are material price increases on supplies, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Expansion of our operations to and offering our services in markets outside of the U.S. subjects us to political, economic, legal, operational and other risks that could have a material adverse effect on our business, results of operations, financial condition, cash flows and reputation.
  • If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition and cash flows and could materially harm our reputation.
  • Our ancillary services and strategic initiatives, including, without limitation, our international operations, that we operate or invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one
  • or more of these activities is unsuccessful, our business, results of operations, financial condition and cash flows may be negatively impacted and we may have to write off our investment and incur other exit costs.
  • If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to law, rule or regulation, new competition, a perceived decrease in the quality of service levels at our centers or other reasons, it would have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • If our labor costs continue to rise, including due to shortages, changes in certification requirements and/or higher than normal turnover rates in skilled clinical personnel; or currently pending or future governmental laws, rules, regulations or initiatives impose additional requirements or limitations on our operations or profitability; or, if we are unable to attract and retain key leadership talent, we may experience disruptions in our business operations and increases in operating expenses, among other things, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Our business is labor intensive and could be materially adversely affected if we are unable to attract and retain employees or if union organizing activities or legislative or other changes result in significant increases in our operating costs or decreases in productivity.
  • Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely, including, without limitation, our clinical, billing and collections systems could materially adversely affect our business, results of operations, financial condition and cash flows.
  • The level of our current and future debt could have an adverse impact on our business, and our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants depends on many factors beyond our control.
  • We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.
  • We may be subject to liability claims for damages and other expenses that are not covered by insurance or exceed our existing insurance coverage that could have a material adverse effect on our business, results of operations, financial condition, cash flows and could materially harm our reputation.
  • If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised, which could have a material adverse effect on our ability to accurately report our financial results, the market's perception of our business and our stock price.
  • Deterioration in economic conditions, disruptions in the financial markets or the effects of natural or other disasters, political instability, public health crises or adverse weather events such as hurricanes, earthquakes, fires or flooding could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Provisions in our organizational documents, our compensation programs and policies and certain requirements under Delaware law may deter changes of control and may make it more difficult for our stockholders to change the composition of our Board of Directors and take other corporate actions that our stockholders would otherwise determine to be in their best interests.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: ABR, adjunct, affectionately, Agile, ahead, APTC, Arabia, auto, backup, belong, belonging, biometric, blocking, brand, Brazil, career, caregiving, CDC, CDI, CFO, child, childcare, China, climate, cloud, coach, coaching, cohort, color, communicable, constructive, cornerstone, CPRA, cultivate, DailyPay, differentially, digital, directory, disaster, distance, distancing, divisional, downturn, drove, Eastern, EDPB, EEA, efficacy, elder, empower, energy, entirety, environmental, equitable, ethnicity, everyday, Excellence, expert, extinguished, extraordinary, fatality, FDA, Feedback, feel, footprint, forgo, Forte, front, fundraising, furlough, grandchildren, guertin, guide, guided, hall, hardship, Headspace, heightened, heightening, HIF, household, hypoxia, importantly, incentivize, inception, inquiring, interoperability, journey, Kingdom, layer, layoff, LeAnne, leave, live, log, Malaysia, masking, meantime, meditation, mental, overhead, overnight, overseeing, overtime, pandemic, passion, path, paula, payday, persist, persisted, pet, PII, pipeline, Poland, Portugal, PPE, Prime, priority, procure, procuring, progressively, proud, race, rapid, reallocate, reborrowed, recession, redistribution, referenced, reinforced, remote, remotely, repair, representation, resumption, resurgence, RNs, RodriguezChief, role, scientific, shape, sharp, shawn, shelter, Shield, sick, Singapore, SNP, Society, SOFR, steering, student, succeed, superseding, surface, taxation, telephonic, Tomorrow, top, town, traction, tragedy, transparency, underpinned, underscored, understood, undocumented, unemployed, unemployment, unprecedented, unrelated, unrest, vaccinated, vaccine, VBC, vice, Village, Vitality, water, widespread, winstel, woman, women, workforce
Removed: accredit, accreditation, apparent, Baxter, behavioral, broadened, Bulletin, Calhoun, certifying, Chin, chronically, conform, covering, David, decide, designation, discrimination, dispensed, dispose, divest, doctrine, Dr, EHB, elevated, erythropoietin, evolution, exceeding, excise, fluctuated, Glisson, grauer, guaranteeing, guarantor, half, house, identification, ill, informational, initiation, Interbank, interdependent, invalid, lawsuit, learned, lessee, licensing, London, Lori, lowering, medication, mentioned, notional, outpaced, Paladina, palliative, Paulsen, peter, pool, portfolio, President, proper, provisional, quantify, questioned, randomly, reimburse, Robert, Roger, rulemaking, Seismic, slightly, spent, stimulated, supportable, surveying, target, tranche, transitioned, uncertified, unrestricted, withdrawal, Zan